The National Cancer Data Base report on bladder carcinoma

Cancer

Volumn 78, Issue 7, 1996, Pages 1505-1513

  Fleshner, Neil E ^a   Herr, Harry W ^a   Stewart, Andrew K ^b   Murphy, Gerald P ^c   Mettlin, Curtis ^d   Menck, Herman R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

^c NORTHWEST HOSPITAL   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

bladder carcinoma; chemotherapy; cystectomy; National Cancer Data Base; radiotherapy; surgery; survival; transitional cell carcinoma; transurethral resection; treatment

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; DATA BASE; FEMALE; GENDER; HUMAN; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; AMERICAN CANCER SOCIETY; CARCINOMA, TRANSITIONAL CELL; CASE MANAGEMENT; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REGISTRIES; SOCIETIES, MEDICAL; SURGERY; SURVIVAL RATE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 0029794002     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961001)78:7<1505::AID-CNCR19>3.0.CO;2-3     Document Type: Article

References (24)

1. Cancer Facts and Figures: 1996. Atlanta: American Cancer Society, 1995.
2. Burch JD, Rohan TE, Howe GE. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 1989;44:622.
3. Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, editors. Urology. 6th edition. Philadelphia: W.B. Saunders, 1992:00-00.
4. Pederson-Bjergaard J, Ersboll J, Hansen V. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988;318:1028.
5. Quilty PM, Kerr GR. Bladder cancer following low or high dose pelvic radiation. Clin Radiol 1987;38:583.
6. Scher HI. High risk papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. J Urol 1994;152:568.
7. Jessup JM, Steele GD, Winchester DP. Introduction. In: Steele GD, Jessup JM, Winchester DP, Menck HR, Murphy GP, editors. National Cancer Data Base Annual Review of Patient Care, 1995. Atlanta: American Cancer Society, 1995:1-11.
8. Percy C, Van Holten V, Muir C. International classification of diseases for oncology. 2nd edition. Geneva: World Health Organization, 1990.
9. American Joint Committee on Cancer. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging cancer. 4th edition. Philadelphia: J.B. Lippincott Co., 1992.
10. Kassabian VS, Graham SD. Urologic and male genital cancers. In: Murphy GP, Lawrence W, Lenhard RE, editors. American Cancer Society textbook of clinical oncology. 2nd edition. Atlanta: American Cancer Society, 1995:313-29.
11. Jones GW, Mettlin C, Murphy GP. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545.
12. Center for Disease Control. Cigarette smoking among adults. MMWR Morb Mortal Wkly Rep 1992;41:354.
13. Russo P, Fleshner NE, Garland J, O'Sullivan M, Trambert R, Fair WR, et al. Prevalence and patterns of tobacco use in patients with bladder cancer. J Urol 1996;155:691.
14. Howard J, Hankey BF, Greenberg RS, Austin DF, Correa P, Chen VW, et al. A collaborative study of differences in the survival rates of Black patients and White patients with cancer. Cancer 1992;69:2349.
15. Office of Technological Assessment, U.S. Congress. Does health insurance make a difference? Washington DC: U.S. Government Printing Office; 1992 OTA-BP-H-99.
16. Burns PB, Swanson GM. Risk of urinary bladder cancer among blacks and whites: the role of cigarette use and occupation. Cancer Causes Control 1991;2:371.
17. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase MU 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15:1077.
18. Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1992;1:481.
19. Esrig D, Elmajian D, Groshen S. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259.
20. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmend T, Weisberger LR, et al. Preliminary results of M-VAC for transitional cell carcinoma of the urothelium. J Urol 1985; 133:403.
21. Igawa M, Urakami S, Shiina H, Ishibe T, Kadene H, Usui T. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response. Br J Urol 1995;76:321.
22. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital Experience. J Urol 1989;142:289.
23. Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1453.
24. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823.